Search results
PROMOTED
Author(s):
Nicolas M Van Mieghem
,
Kendra J Grubb
,
David Hildick-Smith
,
et al
Start date:
Mar 26, 2024
Embolic Protection
Author(s):
Jennifer Franke
,
Horst Sievert
Added:
3 years ago
Article
Timir K Paul
Job title: Associate Professor & Director, Interventional Cardiology
Author
Author(s):
William R Colyer Jr
,
Christopher J Cooper
Added:
3 years ago
Atherosclerotic renal artery stentosis (RAS) is a frequently recognised cause of secondary hypertension and chronic kidney disease.1–4 Revascularisation of RAS with angioplasty and stenting is often performed with the goals of improved blood pressure control and preserving or improving renal function.5 However, renal artery stenting is sometimes associated with acute worsening of renal function.6…
View more
Author(s):
Samir R Kapadia
Added:
1 year ago
TCT 22 - In this short interview, Dr Samir Kapadia (Cleveland Clinic, OH, US) outlines the findings of the PROTECTED-TAVR trial, which aimed to demonstrate the performance of Boston Scientific's Sentinel® Cerebral Protection System in transcatheter aortic valve replacement.
In this study, 3000 patients were randomized to receive either TAVR with the Sentinel system or TAVR without intervention…
View more
Need for Embolic Protection During Transcatheter Aortic Valve Implantation: An Interventionalist’s…
Author(s):
Herbert G Kroon
,
Nicolas M Van Mieghem
Added:
3 years ago
Article
Author(s):
Salvatore Brugaletta
,
Hector M Garcia-Garcia
,
Patrick W Serruys
Added:
3 years ago
The identification of vulnerable plaques has been a longstanding challenge for interventional cardiologists. Plaque composition is regarded as an important feature for assessment of plaque vulnerability. Histopathologists have in particular shown that the type of plaque most commonly prone to rupture in vivo is the thin-cap fibroatheroma (TCFA), in which the presence of lipid core (also called…
View more
Author(s):
Florian Hecker
,
Mani Arsalan
,
Thomas Walther
Added:
3 years ago
Transcatheter aortic valve replacement (TAVR) has become the default treatment option for high-risk patients with aortic stenosis (AS) and, based on heart team discussion, an alternative to surgical aortic valve replacement (SAVR) in intermediate-risk patients.
TAVR has led to a paradigm shift in the basic therapeutic principle to treat AS: calcifications, in some patients quite excessive, are…
View more
Author(s):
Alexandre Abizaid
Added:
3 years ago
In treating thrombus-loaded lesions through percutaneous coronary intervention (PCI) in the settings of acute myocardial infarction (MI), saphenous vein grafts (SVGs) and acute coronary syndromes (ACS), distal embolisation is a recognised prevalent occurrence, adversely affecting reperfusion and mortality rates. Thus, efficient management of embolisation, in terms of both reduced occurrence and…
View more
Author(s):
Holger Eggebrecht
,
Philipp Kahlert
,
Polykarpos Patsalis
,
et al
Added:
3 years ago
Transcatheter aortic valve implantation (TAVI) has recently emerged as a novel, minimally invasive treatment option for patients with symptomatic severe aortic valve stenosis deemed at high risk of conventional surgery due to excessive co-morbidities.1,2 Clinical results of TAVI are encouraging and the number of patients treated with this new method continues to grow exponentially in an…
View more